SAN DIEGO--(BUSINESS WIRE)--Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced completion of enrollment in NB-301, the largest of its Phase III clinical trials, for Contrave®, its lead obesity product candidate. This represents completion of enrollment in the second of four Phase III trials of Contrave.
